<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>This umbrella review examined systematic reviews of deprescribing studies by characteristics of intervention, population, medicine, and setting. Clinical and humanistic outcomes, barriers and facilitators, and tools for deprescribing are presented. The Medline database was used. The search was limited to systematic reviews and meta-analyses published in English up to April 2022. Reviews reporting deprescribing were included, while those where depre-scribing was not planned and supervised by a healthcare professional were excluded. A total of 94 systematic reviews (23 meta--analyses) were included. Most explored clinical or humanistic outcomes (70/94, 74 %); less explored attitudes, facilitators, or barriers to deprescribing (17/94, 18 %); few focused on tools (8/94, 8.5 %). Reviews assessing clinical or humanistic outcomes were divided into two groups: reviews with <italic>deprescribing intervention trials</italic> (39/70, 56 %; 16 reviewing specific deprescribing interventions and 23 broad medication optimisation interventions), and reviews with <italic>medication cessation trials</italic> (31/70, 44 %). Deprescribing was feasible and resulted in a reduction of inappropriate medications in reviews with <italic>deprescribing intervention trials</italic>. Complex broad medication optimisation interventions were shown to reduce hospitalisation, falls, and mortality rates. In reviews of <italic>medication cessation trials,</italic> a higher frequency of adverse drug withdrawal events underscores the importance of prioritizing patient safety and exercising caution when stopping medicines, particularly in patients with clear and appropriate indications.</p>
</abstract>

This umbrella review examined systematic reviews of deprescribing studies by characteristics of intervention, population, medicine, and setting. Clinical and humanistic outcomes, barriers and facilitators, and tools for deprescribing are presented. The Medline database was used. The search was limited to systematic reviews and meta-analyses published in English up to April 2022. Reviews reporting deprescribing were included, while those where depre-scribing was not planned and supervised by a healthcare professional were excluded. A total of 94 systematic reviews (23 meta--analyses) were included. Most explored clinical or humanistic outcomes (70/94, 74 %); less explored attitudes, facilitators, or barriers to deprescribing (17/94, 18 %); few focused on tools (8/94, 8.5 %). Reviews assessing clinical or humanistic outcomes were divided into two groups: reviews with deprescribing intervention trials (39/70, 56 %; 16 reviewing specific deprescribing interventions and 23 broad medication optimisation interventions), and reviews with medication cessation trials (31/70, 44 %). Deprescribing was feasible and resulted in a reduction of inappropriate medications in reviews with deprescribing intervention trials. Complex broad medication optimisation interventions were shown to reduce hospitalisation, falls, and mortality rates. In reviews of medication cessation trials, a higher frequency of adverse drug withdrawal events underscores the importance of prioritizing patient safety and exercising caution when stopping medicines, particularly in patients with clear and appropriate indications.

Deprescribing: An umbrella review

University of Ljubljana Faculty of Pharmacy

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Deprescribing: An umbrella review"}

This umbrella review examined systematic reviews of deprescribing studies by characteristics of intervention, population, medicine, and setting. Clinical and...

Deprescribing: An umbrella review

Publié en ligne: 30 mai 2024

Pages: 249 - 267

Accepté: 04 janv. 2024

DOI: https://doi.org/10.2478/acph-2024-0011

Mots clés
deprescription, drug discontinuation, drug withdrawal, drug tapering, umbrella review

© 2024 Nuša Japelj et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Deprescribing: An umbrella review

Publié en ligne: 30 mai 2024

Pages: 249 - 267

Accepté: 04 janv. 2024

DOI: https://doi.org/10.2478/acph-2024-0011

Mots clésdeprescription, drug discontinuation, drug withdrawal, drug tapering, umbrella review

© 2024 Nuša Japelj et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
deprescription, drug discontinuation, drug withdrawal, drug tapering, umbrella review